Migrating legacy data to a modern laboratory information management system (LIMS) is often seen as a complex and challenging process, especially for regulated laboratories dealing with decades of historical records. Legacy data may exist in various formats and structures, often spread across multiple systems. This data—whether structured or unstructured, machine- or human-generated—is often retained for legal, regulatory, or historical purposes, even if it is no longer actively used.   

According to the National Institute for Children’s Health Quality, “Ten percent of babies in the United States are born prematurely, facing increased risks of health issues and complications”. At LabWare’s North America Customer Education Conference (CEC), Sera Prognostics, Inc., a client dedicated to improving maternal healthcare and fetal medicine, shared how LabWare LIMS supports their innovative diagnostic process, which helps to predict pre-term complications.  

Photo: via Yposkesi

ALTRINCHAM, UK-- LabWare Limited

Yposkesi, an SK pharmteco company, is one of Europe’s largest Contract Development and Manufacturing Organizations (CDMO) for gene therapy viral vector manufacturing, which, after a formal selection process of the leading LIMS solutions within the market, chose to implement LabWare as their LIMS solution for their Corbeil-Essonnes (France) site.

Note: This story was featured in the April 2021 edition of LABInsights and has been edited for clarity.

Denkavit recently expanded the functionality of its LIMS, adding options for inventory management, tracking consumption and ordering lab consumables. To facilitate these additions to an application the animal feed manufacturer has been using since 2014, Denkavit’s LIMS supplier adapted its existing inventory management template and added new, client-specific functionalities.

A recent New York Times article highlighted the manufacturing, testing, and distribution processes for the Pfizer-BioNTech Covid-19 messenger RNA (mRNA) based vaccine.

The careful execution, integration, and optimization of multiple steps are critical to the vaccine's safety, effectiveness, and efficient delivery. Pfizer's multifaceted vaccine process takes 60 days from start to finish across numerous locations involving thousands of employees. More than half of this effort goes to quality testing, which must adhere to vaccine manufacturing regulatory requirements, including compliance with current Good Manufacturing Practices (cGMP).